Post by Biocartis

June marks 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, highlighting the growing role of immune-based approaches, such as immune checkpoint inhibitors, across multiple cancer types 📈 In colorectal cancer (CRC), MSI-H tumors arise from deficient DNA mismatch repair, leading to 𝐡𝐢𝐠𝐡 𝐥𝐞𝐯𝐞𝐥𝐬 𝐨𝐟 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐡𝐚𝐧𝐠𝐞𝐬 and the formation of neoantigens that can 𝐭𝐫𝐢𝐠𝐠𝐞𝐫 𝐚𝐧 𝐢𝐦𝐦𝐮𝐧𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞. 𝐓𝐮𝐦𝐨𝐫𝐬 𝐜𝐚𝐧 𝐞𝐯𝐚𝐝𝐞 this response by activating immune checkpoint pathways such as PD-1 / PD-L1 and CTLA-4, which reduce immune activity against cancer cells… 💡 Immune checkpoint inhibitors, including 𝐎𝐏𝐃𝐈𝐕𝐎® (𝐧𝐢𝐯𝐨𝐥𝐮𝐦𝐚𝐛) 𝐚𝐧𝐝 𝐘𝐄𝐑𝐕𝐎𝐘® (𝐢𝐩𝐢𝐥𝐢𝐦𝐮𝐦𝐚𝐛), block these pathways and restore immune activity. This allows the immune system to recognize and eliminate tumor cells, 𝐡𝐞𝐥𝐩𝐢𝐧𝐠 𝐭𝐨 𝐬𝐥𝐨𝐰 𝐨𝐫 𝐬𝐭𝐨𝐩 𝐭𝐮𝐦𝐨𝐫 𝐠𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐬𝐩𝐫𝐞𝐚𝐝. 💪 Reliable MSI testing is therefore essential to identify patients who may benefit from immunotherapy. 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭* 👉 https://lnkd.in/eH3maF9y #CancerImmunotherapyAwarenessMonth #MSI #CDx #CRC #Biocartis #Idylla *𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴. 𝐴𝑝𝑝𝑟𝑜𝑣𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑈𝑆 𝑢𝑛𝑑𝑒𝑟 P250005. 𝘖𝘗𝘋𝘐𝘝𝘖® 𝘢𝘯𝘥 𝘠𝘌𝘙𝘝𝘖𝘠® 𝘢𝘳𝘦 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬𝘴 𝘰𝘧 𝘉𝘳𝘪𝘴𝘵𝘰𝘭-𝘔𝘺𝘦𝘳𝘴 𝘚𝘲𝘶𝘪𝘣𝘣 𝘊𝘰𝘮𝘱𝘢𝘯𝘺.